About ATP synthase F(0) complex subunit a
ATP synthase F(0) complex subunit a (MT-ATP6) is a protein
from Homo sapiens identified by UniProt accession
P00846, 226 residues long.
MolForge cross-references it against 0 known binders and
225 disease associations.
Target properties
| Protein name | ATP synthase F(0) complex subunit a |
|---|
| UniProt accession | P00846 |
|---|
| Gene | MT-ATP6 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 226 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (225)
Diseases linked to this target (Open Targets).
- Leigh syndrome · score 0.77
- Leber hereditary optic neuropathy · score 0.74
- NARP syndrome · score 0.70
- mitochondrial disease · score 0.67
- mitochondrial complex 5 (ATP synthase) deficiency, mitochondrial type 1 · score 0.66
- Sensory ataxic neuropathy - dysarthria - ophthalmoparesis · score 0.59
- MELAS · score 0.57
- MELAS syndrome · score 0.57
- leigh syndrome due to mitochondrial complex iv deficiency · score 0.52
- mitochondrial complex IV deficiency, nuclear type 22 · score 0.52
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-P00846-F1 | alphafold | PREDICTED | 88.93 | — |
Amino-acid sequence (226 residues)
MNENLFASFI APTILGLPAA VLIILFPPLL IPTSKYLINN RLITTQQWLI KLTSKQMMTM HNTKGRTWSL MLVSLIIFIA TTNLLGLLPH SFTPTTQLSM NLAMAIPLWA GTVIMGFRSK IKNALAHFLP QGTPTPLIPM LVIIETISLL IQPMALAVRL TANITAGHLL MHLIGSATLA MSTINLPSTL IIFTILILLT ILEIAVALIQ AYVFTLLVSL YLHDNT
Explore ATP synthase F(0) complex subunit a with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets